|
US581916A
(en)
|
|
1897-05-04 |
|
Harvester |
|
US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
|
US4342776A
(en)
|
1979-11-05 |
1982-08-03 |
Merck & Co., Inc. |
4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
|
|
US4399276A
(en)
|
1981-01-09 |
1983-08-16 |
Kabushiki Kaisha Yakult Honsha |
7-Substituted camptothecin derivatives
|
|
US4473692A
(en)
|
1981-09-04 |
1984-09-25 |
Kabushiki Kaisha Yakult Honsha |
Camptothecin derivatives and process for preparing same
|
|
JPS5839685A
(ja)
|
1981-09-04 |
1983-03-08 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体及びその製造法
|
|
JPS58154582A
(ja)
|
1982-03-10 |
1983-09-14 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体およびその製造法
|
|
US4526988A
(en)
|
1983-03-10 |
1985-07-02 |
Eli Lilly And Company |
Difluoro antivirals and intermediate therefor
|
|
JPS6019790A
(ja)
|
1983-07-14 |
1985-01-31 |
Yakult Honsha Co Ltd |
新規なカンプトテシン誘導体
|
|
DE3587500T2
(de)
|
1984-12-04 |
1993-12-16 |
Lilly Co Eli |
Tumorbehandlung bei Säugetieren.
|
|
US5223608A
(en)
|
1987-08-28 |
1993-06-29 |
Eli Lilly And Company |
Process for and intermediates of 2',2'-difluoronucleosides
|
|
US5004758A
(en)
|
1987-12-01 |
1991-04-02 |
Smithkline Beecham Corporation |
Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
|
|
IL89220A
(en)
|
1988-02-11 |
1994-02-27 |
Bristol Myers Squibb Co |
Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
|
|
ES2165346T3
(es)
|
1989-09-15 |
2002-03-16 |
Res Triangle Inst |
Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6407115B1
(en)
|
1991-01-16 |
2002-06-18 |
Daiichi Pharmaceutical Co., Ltd. |
Hexa-cyclic compound
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
EP0563475B1
(en)
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
FR2707988B1
(fr)
|
1993-07-21 |
1995-10-13 |
Pf Medicament |
Nouveaux dérivés antimitotiques des alcaloïdes binaires du catharantus rosesus, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
|
|
EP0871490B1
(en)
|
1995-12-22 |
2003-03-19 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
|
WO1999040942A1
(en)
|
1998-02-10 |
1999-08-19 |
Yoshitomi Pharmaceutical Industries, Ltd. |
Preparations with controlled release
|
|
JP2003530297A
(ja)
|
1998-10-16 |
2003-10-14 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， リプリゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
Ｖｉｐアンタゴニストを用いる併用療法
|
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
|
HK1049997B
(en)
|
1999-11-24 |
2007-02-23 |
Immunogen, Inc. |
Cytotoxic agents comprising taxanes and their therapeutic use
|
|
WO2001058479A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7771951B2
(en)
|
2001-12-03 |
2010-08-10 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
|
ES2369542T3
(es)
|
2002-07-31 |
2011-12-01 |
Seattle Genetics, Inc. |
Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
|
|
EP1534674A4
(en)
|
2002-08-02 |
2007-11-28 |
Immunogen Inc |
CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
|
|
EP1542723B1
(en)
|
2002-08-16 |
2011-02-23 |
ImmunoGen, Inc. |
Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
|
|
WO2004033036A2
(en)
|
2002-10-04 |
2004-04-22 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CA2672581A1
(en)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
|
|
WO2008130158A1
(en)
|
2007-04-19 |
2008-10-30 |
Dong-A Pharmaceutical. Co., Ltd |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
|
AU2009203464A1
(en)
|
2008-01-11 |
2009-07-16 |
Forerunner Pharma Research Co., Ltd. |
Anti-CLDN6 antibody
|
|
NZ588884A
(en)
|
2008-04-30 |
2013-05-31 |
Immunogen Inc |
Cross-linkers and their uses
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
US8025098B2
(en)
|
2008-06-18 |
2011-09-27 |
Xyleco, Inc. |
Processing hydrocarbons
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
EP3689911B1
(en)
|
2009-11-11 |
2024-08-21 |
Astellas Pharma Inc. |
Antibodies specific for claudin 6 (cldn6)
|
|
US8840902B2
(en)
|
2010-03-16 |
2014-09-23 |
Biontech Ag |
Tumor vaccination involving a humoral immune response against self-proteins
|
|
EP2404936A1
(en)
*
|
2010-07-06 |
2012-01-11 |
Ganymed Pharmaceuticals AG |
Cancer therapy using CLDN6 target-directed antibodies in vivo
|
|
EP3026064B1
(en)
|
2011-05-13 |
2018-10-17 |
Ganymed Pharmaceuticals GmbH |
Antibodies for treatment of cancer expressing claudin 6
|
|
US10195288B2
(en)
|
2012-10-11 |
2019-02-05 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate
|
|
WO2014075697A1
(en)
*
|
2012-11-13 |
2014-05-22 |
Biontech Ag |
Agents for treatment of claudin expressing cancer diseases
|
|
IL282953B2
(en)
*
|
2012-11-13 |
2026-02-01 |
Tron Translationale Onkologie An Der Johannes Gutenberg Univ Mainz Gemeinnutzige Gmbh |
Agents for the treatment of claudin-expressing cancers
|
|
WO2015014376A1
(en)
|
2013-07-31 |
2015-02-05 |
Biontech Ag |
Diagnosis and therapy of cancer involving cancer stem cells
|
|
AU2014346792A1
(en)
|
2013-11-06 |
2016-06-02 |
Abbvie Stemcentrx Llc |
Novel anti-claudin antibodies and methods of use
|
|
CN106459165B
(zh)
|
2014-04-01 |
2021-04-20 |
拜恩科技细胞&基因治疗有限公司 |
密封蛋白-6特异性免疫受体和t细胞表位
|
|
CN108431026B
(zh)
|
2015-11-02 |
2023-02-17 |
豪夫迈·罗氏有限公司 |
制备岩藻糖基化和去岩藻糖基化形式的蛋白质的方法
|
|
PE20181302A1
(es)
|
2015-12-04 |
2018-08-09 |
Abbvie Stemcentrx Llc |
Nuevos anticuerpos anti-claudina y sus metodos de uso
|
|
SG11202002114RA
(en)
|
2017-09-18 |
2020-04-29 |
Univ California |
Claudin6 antibodies and methods of treating cancer
|
|
DK3941946T3
(da)
|
2019-03-20 |
2025-03-24 |
Univ California |
Claudin-6-antistoffer og lægemiddelkonjugater
|
|
WO2020191344A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 bispecific antibodies
|